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 Abstract 
 
 The goal of this research was to reduce disease in an adoptive transfer model of 
colitis using an immunomodulatory therapy, hemin, while correlating this response to 
changes in cytokines and effector T-cell differentiation. Inflammatory bowel disease 
(IBD) is a consequence of immune system dysregulation, mediated by the microbiomes 
composition (Gálvez, 2014). IBD is most prevalent and rising in developed parts of the 
world such as the United States where 1.5 million people and Europe where 2.2 million 
people are affected (Ananthakrishnan, 2015). Research for IBD in recent years has 
significantly advanced our knowledge of the complex pathways and interactions 
involved, however a complete and long lasting treatment remains unidentified. The rate-
limiting enzyme HO-1 has been found to increase pools of regulatory T-cells (T-regs), 
while decreasing pools of pro-inflammatory Th17 cells in a chemically induced model of 
colitis. Here, the in-life phase which focused on body weight and video endoscopy 
support other primary outcomes from multiplex immunoassays and fluorescence 
activated cell sorting (FACS) from blood, colon, spleen, and mesenteric lymph node 
samples in an adoptive transfer model of colitis in mice. Pro-inflammatory cytokines 
IFN-γ and TNF-α and CD4+ T-cells in the blood at study conclusion were found to be 
significantly decreased in the hemin group, as were CD4+CD39+ T-cells in the blood 
from days 28-56. Further, in life data suggests a positive treatment effect showing a trend 
with higher body weights and lower endoscopy scores. Together these data demonstrate 
that hemin acts in an anti-inflammatory manner by modulating pathogenic T-cell 
proliferation and production of key pro-inflammatory cytokines.
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Chapter I 
Introduction 
 
Inflammatory Bowel Disease Background 
 
Crohn's disease (CD) and ulcerative colitis (UC) are diseases where chronic 
inflammation of the epithelial lining within the intestines results from a dysregulated 
immune system. Together, these ailments are classified as inflammatory bowel disease 
(IBD). Although there has been significant progress treating IBD, many studies have 
shown that the incidence and prevalence of IBD has been on the rise over the past half 
century in developed continents such as North America and Europe. Annual incidences 
of UC in North America and Europe were 24.3 and 19.2(12.7 and 20.2 for CD) per 
100,000 persons-years, respectively, whereas in Asia and the Middle East were only 
6.3(5.0 for CD) per 100,000 persons-years. (Molodecky et al., 2012). 1.5 million 
Americans and 2.2 million Europeans are affected, and meta-analysis has shown time 
trend incidence increases in these continents (Ananthakrishnan, 2015). The increased 
incidence of IBD and the differences between populations are likely due to a variety of 
factors. Since IBD is an autoimmune regulated disease, data support that responses can 
be affected by factors such as commensal bacteria, genetic predisposition, immune 
response, and environmental conditions (FIOCCHI, 2005). Furthermore, disease is 
perpetuated by factors produced after the initiation of disease such as oxidative stress 
from reactive oxygen species which damage tissue health (Rezaie, Parker, & Abdollahi, 
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2007). Supporting this, genetically modified mice lacking antioxidant enzymes develop 
spontaneous colitis (Esworthy, Kim, Doroshow, Leto, & Chu, 2013).  Patients with IBD 
suffer from symptoms such as weight loss, pain, diarrhea, and rectal bleeding. These 
symptoms can often be severe and cause hospitalization during bouts of IBD (Gálvez, 
2014,). The standard of care is currently up for discussion, as the emergence of 
immunomodulatory therapies like infliximab are becoming increasingly used over 
traditional therapies like 5-aminosalicylic acid or corticosteroids (Travis, 2006, Lee, 
Sanderson, & Irving, 2012). Typically, when treating IBD, the first goal is to limit the 
damage during inflammatory bouts by using 5-aminosalicylic acid and/or corticosteroids 
however, steroids can lead to a dependency and difficulty remaining in remission. To 
combat this, patients can begin treatments with immunosuppressive therapies 
azathioprine and methotrexate but each has several limiting factors such as a significant 
increase in lymphoma in azathioprine patients and hepatotoxicity in Methotrexate 
patients (Engel & Neurath, 2010). New biologic therapies have targeted cytokines known 
to be pathogenic in IBD, such the anti-TNFα monoclonal antibody Infliximab. The 
efficacies of these treatments are under debate and could have diminished effects due to 
anti-Infliximab antibodies (Nanda, Cheifetz, & Moss, 2012). Additionally, the cost of 
IBD in the United States per patient is over $18,000 per year, with anti-TNFα therapies 
costing up to $4,000 per infusion compared to 5-aminosalicylic acid compounds like 
sulfasalazine, which cost $50 per month (Park & Bass, 2011). The newest approved 
therapies are integrin inhibitors like vedolizumab, which block T-cell transportation to 
the gut (Feagan et al., 2013).  
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The main cell type involved in the autoimmune response is T-cells. The potential 
for T-cells to differentiate into a specific lineage: Th1, Th2, Th17, or T-regs plays a key 
role in the development of the autoimmune response in IBD and other autoimmune 
diseases (Cheng et al., 2009, Dieleman et al., 1998, Luger et al., 2008). Therefore, it is 
critical to fully understand and characterize T-cell distribution, differentiation, and 
activation pathways when researching this complex disease. Immune system 
dysregulation is a hallmark of IBD, the balance of T-cell subsets plays a critical role in 
establishing gut homeostasis but can be disrupted by a combination of genetic, 
environmental, and host microbiome factors. Furthermore, the balance between and 
effect of each subset is largely mediated by cytokines (Gálvez, 2014, Kucharzik et al., 
2006). More recently, there has been a strong interest in understanding the role of genetic 
factors, such as mutations to the IL-10 receptor being associated with early onset CD 
(Colombel, 2014). Findings such as these highlights the importance of treating IBD 
patients individually, as there may be very specific differences leading to different 
treatment avenues. Combination therapy based on individual patient immune responses, 
microbiota, and genetic factors are likely the next approach in developing new IBD 
treatments. Identifying and fully elucidating the pathways involved in IBD remains the 
most important treatment variable. As such, research that focuses on further unravelling 
these pathways and how they interact with each other is highly needed. 
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Gut Microbiome and T-Cells 
 
The intestinal lining is the first barrier in host defense, limiting pathogenic 
responses by functioning as a semi-permeable wall. When this barrier is damaged by 
local inflammation, it becomes more permeable, allowing passage of bacteria, 
electrolytes, antigens, and other macromolecules, which attribute to the pathogenesis of 
IBD (Berkes, 2003, Liu, Li, & Neu, 2005). While paracellular and transcellular passage 
are normal functions of the epithelium, these are increased during the inflammatory 
response and coupled with passage through lesions and can lead to the development of 
disease (Lewis & McKay, 2009, Lewis et al., 2010). This insult to the tissue coincides 
with changes in the way the host microbiota is recognized by T-cells, ultimately leading 
to dysregulation of the immune system signified by increased T-cell activation and 
differentiation of pathogenic T-cells (Figure 1) (Gálvez, 2014). The immune response 
and dysregulation in IBD is in large part mediated by effector T-cells Th1, Th2, Th17, 
and T-regs. Th1 and Th2 cells were initially the focus of IBD research, however since the 
discovery of Th17 cells and T-regs a large importance has been placed on eluding their 
roles in autoimmune disorders. The balance between Th17 cells and T-regs, discussed in 
detail later, has been established as a chief regulator of autoimmune disease (Abdulahad, 
Boots, & Kallenberg, 2010, Berger, 2000).  
The bacterial flora composition in the gut is of particular importance in the 
context of IBD due to its ability to either stabilize or initiate an immune response by 
affecting T-cell responses. Decreased complexity of the gut microbiome has been linked 
to increased disease; stress, diet, genetics, drugs, and other factors can lead to losing the 
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stability of gut homeostasis and allow the development of chronic inflammation (Kostic, 
Xavier, & Gevers, 2014). Demonstrating how vital the microbiome is to disease, studies 
conducted in germ free animals show that disease severity in the DSS model is repressed 
(KITAJIMA, MORIMOTO, SAGARA, SHIMIZU, & IKEDA, 2001). Indeed, bacteria 
such as Escherichia coli and the genus Fusobacterium have been found at increased 
levels in IBD patients (Kostic, Xavier, & Gevers, 2014). While the microbiome as a 
whole is needed and partially responsible for disease development, there are specific 
bacteria that can be helpful. For instance, Clostridium, a common intestinal bacterium 
can be anti-inflammatory by inducing T-reg proliferation (Chiba & Seno, 2011). Findings 
such as these indicate that researching responses to specific bacteria could potentially 
lead to new therapeutic targets. The microbiome, having this bimodal functionality to 
stimulate and inhibit disease highlights the importance and complexity of the microbiome 
when considering the pathogenesis of IBD by T-cells. Also playing a role in immune 
system sensitivity to the microbiome are genetics. NOD2, responsible for activation of 
transcription factor NF-κB in monocytes is associated with CD when mutated (Hugot et 
al., 2001). While NOD2 can have different variations of mutations, pathogenic mutations 
lead to over activation of NOD2/ NF-κB leading to increased monocyte proliferation and 
microbial recognition (Hugot et al., 2001). Advancements increasing our understanding 
of the relationship between host microbiome and genetics are important due to the 
complexity of IBD’s pathogenesis. With these new findings, it appears that treatments in 
the future will need to consider the patients’ specific immune response, bacterial flora, 
and genetic background.  
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Effector T-Cell Differentiation and Cytokines 
 
T-cell precursors go through negative selection in the thymus, which forces cells 
that have self-reactivity to undergo apoptosis, thus preventing the adaptive immune 
response from attacking its own healthy cells. Self-tolerant T-cells then become effector 
T-cells, derived from these naïve precursors, and the conditions in the cell, the 
microbiome, and genetics can drive the proliferation of specific T-cell subsets (Gálvez, 
2014, Josefowicz, Lu, & Rudensky, 2012). While there is a range of phenotypically 
distinct effector T-cells, they can be identified based on the expression of particular cell 
surface molecules; these markers not only allow for the identification of subsets, but also 
directly determine effector functionality. The most basic subsets of T-cells are the CD4+ 
and CD8+ lineages. The CD8+ lineage T-cells become cytotoxic killers, whereas the 
CD4+ lineage have the potential to become Th1, Th2, Th17, or T-regs (Germain, 2002, 
Harty, Tvinnereim, & White, 2000) (Figure 2.). The differentiation into Th1, Th2, Th17, 
or T-reg lineages is determined by interactions between the naïve T-cell, antigen 
presenting cells, and the cytokine milieu. Cytokines can either be produced by the T-cell 
or surrounding cells and effect the immune response. One of the ways cytokines affects 
the immune response is by driving T-cell differentiation toward a specific T-cell 
phenotype. Certain cytokines are strongly associated with each subset, for example, TGF-
β is associated with more Th17 differentiation and IFN-γ both stimulates differentiation 
into and is produced by Th1 T-cells (Zhu, Yamane, & Paul, 2010). Improperly balanced 
effector T-cells Th1/Th2/Th17 and T-reg patterns are associated with numerous disease 
states (Cheng et al., 2009, Dieleman et al., 1998, Luger et al., 2008). Cytokines are 
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therefore very important in maintaining the balance between these cell lineages which is 
vital for sustaining a healthy immune system.  
Th1 cells are typically associated with a pro-inflammatory cytokine profile, of 
which the quintessential cytokine is interferon-γ (INF-γ). T-cell precursors are stimulated 
to differentiate into Th1 cells by INF-γ, Th1-cells then also produce INF-γ, generating a 
feedback loop (Zhu, Yamane, & Paul, 2010). This feedback loop is associated with 
unregulated autoimmune responses and tissue damage and is a treatment target due to its 
ability to potentiate disease (Berger, 2000, Resta–Lenert & Barrett, 2006, Zhu, Yamane, 
& Paul, 2010). Indeed, inflammation in CD is mediated Th1 and Th17 cells again 
signifying the importance of INF-γ in IBD (Fuss, 2008, Zhang, Fuss, Yang, & Strober, 
2013). Research however also indicates that disease may be shunted towards a Th1 or 
Th17 response, finding that INF- γ can promote Th17 development and stop Th1 
development through interactions with antigen presenting cells (Kryczek et al., 2008). By 
contrast, Th2 cells are involved in anti-heminthic and allergic responses, while also being 
antagonistic to the Th1 response in allergic responses (Rotmagnani, 1998). Th2 responses 
are associated with the cytokines IL-4 and IL-13, which have been associated with the 
pathogenesis of UC (Fuss, 2008). IL-4 stimulates naïve T-cell differentiation into Th2 
cells, which then produce both IL-4 and IL-13, treatments targeting these have not been 
successful (Fuss, 2008, Zhu, Yamane, & Paul, 2010).  
IL-12 and IL-23 are dimers, which both consist of one p40 subunit. IL-12 has 
been implicated in Th1 type inflammatory responses, while IL-23 is important in the 
activation of innate immunity such as monocyte activation (Langrish et al., 2004). Past 
research had indicated that treatment with anti-p40 monoclonal antibodies worked by 
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repressing Th1 T-cells, but it has since been discovered that anti-p40 is also responsible 
for repressing Th17 responses through an IL-23 blockade (Luger et al., 2008). Th17 cells, 
like Th1 cells have been described in many autoimmune diseases, are induced by IL-6 
and IL-23 and are most well known for producing the pro inflammatory cytokine IL-17 
(Weaver, Harrington, Mangan, Gavrieli, & Murphy, 2006). Th17 cells also produce the 
transcription factor ROR-γ which further induces the generation of Th17 cells, 
perpetuating inflammation. When ROR-γ is missing, disease dwindles and the affected 
tissue does not have large infiltrates of pathogenic Th17 cells (Ziegler & Buckner, 2009). 
T-regs on the other hand are the primary suppressive cells involved in the reduction of 
pro-inflammatory responses, which are characterized by the expression of transcription 
factor Foxp3 and production of the immunosuppressive cytokine IL-10 (Maynard et al., 
2007). The presence of Foxp3 allows T-regs to act as potent immune suppressors, and 
when missing from the immune system a homeostatic environment cannot be established 
resulting in autoimmune disorders (Josefowicz, Lu, & Rudensky, 2012). The balance 
between the expression levels of these two transcription factors ROR- γ and Foxp3, 
observed in healthy individuals, is the result of a complex pathway with multiple routes 
of induction and repression of Th17 cells and T-regs; when perturbation of this delicate 
balance is thought to be a major factor in the pathogenesis of autoimmune disorders 
(Ziegler & Buckner, 2009). 
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T-Regs and Th17 Cells in Inflammatory Bowel Disease 
 
In recent years, researchers have identified Th17 cells as a powerful driving force 
in the inflammatory cascade causing irregular autoimmune function. As such, studies in 
animal models of colitis have shown that disease can be attenuated by either blocking 
differentiation of Th17 cells, or blocking IL-17, the main inflammatory cytokine 
produced by Th17 cells (Gálvez, 2014). Additionally, blocking the Th17 associated 
transcription factor ROR-γ also results in diminished diseased (Zhang, Fuss, Yang, & 
Strober, 2013). Further research has shown that a portion of Th17 cells can shift their 
function towards a Th1 like phenotype that are necessary for the pathogenesis of IBD 
(Harbour, Maynard, Zindl, Schoeb, & Weaver, 2015). 
T-regs play a critical role suppressing autoimmune responses including the 
inflammation caused by these pathogenic Th17 cells. T-regs express the co-stimulatory 
molecule CTLA-4, which is critical for T-reg mediated suppression (Josefowicz, Lu, & 
Rudensky, 2012). IL-2 was initially a target for IBD treatment, however it became clear 
that it was not imperative to have IL-2 present in order to perpetuate disease (Schimpl et 
al., 2002). When CTLA-4 is blocked however, T-regs lose their suppressive effectiveness 
allowing autoimmune disease to arise (Sakaguchi, Wing, Onishi, Prieto-Martin, & 
Yamaguchi, 2009). This vital suppression function allowing gut homeostasis is supported 
by the findings that when CD4+CD25+ cells, markers associated with T-regs, are 
adoptively transferred into diseased SCID CD4+CD25- mice, disease is fully reversed 
(Liu, Hu, Xu, & Liew, 2003). The balance between pathogenic T-cells and non-
pathogenic T-regs represents a weak spot of the immune response, viruses have been 
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found to target this by causing T-regs to undergo apoptosis resulting in a dysregulated 
autoimmune response and chronic infections, using a correlate human respiratory viral 
infection mouse model using sendai viral infections (Bharat et al., 2010).   
Research has shown that the relationship between T-regs and Th17 cells is very 
complex (Figure 3).  Under inflammatory autoimmune conditions where IL-6 is being 
secreted, such as found in rheumatoid arthritis, it has been shown that T-regs can be 
converted into the Th17 phenotype, further driving the inflammatory response (Komatsu 
et al., 2013). Clinical data from IBD patients supports this discovery; patients had 
increased CD4+ T-cells expressing both IL-17 and Foxp3, suggesting phenotype 
conversion from T-reg to Th17 (Ueno et al., 2013). Conversely, Th17 cells have also 
been shown to stop secreting pro-inflammatory cytokine IFN-γ and promote generation 
of IL-22, which decreases epithelial tissue damage by promoting microbial resistance 
responsible for disease abrogation (Gálvez, 2014). While both cells have been found to 
have functions opposite of their normal state, they can also inhibit one another. When the 
receptor for immunosuppressive cytokine IL-10 loses function in patients, the Th17 
levels increase dramatically (Shouval et al., 2015). The regulation of T-reg proliferation 
is also controlled by epigenetic factors such as the recently described methyltransferase 
Uhrf1. Silencing of Uhrf1 results in spontaneous colitis due to an increased load of Th17 
cells and loss of function of T-regs. (Obata et al., 2014). Finally, corroborating these 
results, further research has shown that Uhrf1 loss results in a TNFα based inflammatory 
cascade leading to the loss of immune homeostasis in the gut (Marjoram et al., 2015). 
Together these recent findings represent an important connection between T-reg function 
and development of IBD due to the actions of Th17 cells.  
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Animal Models of Inflammatory Bowel Disease 
 
The complexity of IBD has been difficult to unravel. Until recently, the only 
options for inducing colitis in an experimental setting were chemical, such as dextran 
sodium sulfate (DSS), tri-nitrobenzene sulfonic acid (TNBS), and oxazolone (Wirtz, 
Neufert, Weigmann, & Neurath, 2007). TNBS predominantly confers a Th1 response, 
oxazolone a Th2 response, and DSS a mixed Th1/Th2 response (Wirtz, Neufert, 
Weigmann, & Neurath, 2007, Dieleman et al., 1998) While these models have been 
useful in the research of IBD, the field has been focusing further on the microbiome and 
T-cells. The development of adoptive transfer mediated models of colitis allows the 
investigation of the pathogenesis pathways in a setting where T-regs are missing and 
naive T-cells are undergoing differentiation into their effector subsets (Kanai et al., 
2006). With such importance having been found in the balance between Th17 cells and 
T-regs, as discussed in the previous section, being able to evaluate a treatment’s effect on 
T-cell proliferation is of high interest. The CD45+CD25- T-cell adoptive transfer model 
researchers are now able evaluate the differentiation and homing of T-cells beginning 
from the naïve state, a truly unique aspect to the model made possible by isolating naïve 
CD45RB HIGH T-cells (Ostanin et al., 2008). A similar naive T-cell sort and transfer for 
CD62L+CD44-, used in this research, also induces disease by isolating the CD45RB 
HIGH T-cells (Figure 4). Some advantages of this model include being able to study the 
earliest stages of disease while focusing T-cell differentiation and proliferation (Ostanin 
et al., 2008). The details of this model will be discussed further in Chapter II. 
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Current Inflammatory Bowel Disease Treatments 
 
The most effective treatments have aimed to alter the T-cell response through 
cytokine inhibition/depletion efforts such as anti-p40 and anti-TNFα. Anti-p40 which 
depletes IL-12 and IL-23 results in the blunting of Th1 and Th17 responses by 
suppressing a key Th17 cytokine IL-17A, has shown efficacy in early testing (Kim et al., 
2012). The discovery of treatments targeting the highly pro-inflammatory cytokine TNFα 
with antagonistic monoclonal antibodies resulted in the most currently viable treatment 
option (Rutgeerts, van Assche, & Vermeire, 2004). The ability of TNFα antagonists to 
trigger apoptosis in monocytes and lymphocytes has led some to question the 
susceptibility of anti-TNFα patients to infectious disease however, little evidence has 
been found to support this concern (Targownik & Bernstein, 2013). Instead, the primary 
worry of anti-TNFα therapy is patient variability, there is a significant number of patients 
that do not have either a short or long term response to treatment. In clinical trials, up to 
40% of patients to not respond to anti-TNFα therapy and up to 46% of responders lose 
response within one year of treatment (Ben-Horin, Kopylov, & Chowers, 2014). When 
drugs such as Infiximab, a common anti-TNFα antibody and IBD treatment, or other 
standards of care such as antibiotics and steroids do not work, the last resort for patients 
is to undergo colectomy in order to surgically remove diseased portions of the intestines 
(Sandborn et al., 2009). Antibiotics have been found to have moderate but varied success 
in treatment (Khan et al., 2011). Steroids are also used in IBD patients, but long term 
steroid treatment is not ideal due to its limited response window (Hanauer, 2002). Even 
with great progression in recent years, the large number of non-responders found among 
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the best treatment option, anti-TNFα, indicate alternate routes in the pathways leading 
towards IBD related inflammation. 
As discussed in previous sections, the balance between Th17 and T-regs has 
advanced to the forefront of IBD research. As recently as 2016, it has been shown that 
mTOR inhibition can function as an IBD treatment due to its ability to restore this critical 
balance in a DSS model of colitis (Hu et al., 2016). Another possible route to treat the 
Th17/T-reg balance is by modulating the microbiome; short chain fatty acid producing 
bacteria, such as the Clostridia species are implicated in the proliferation of T-regs is 
significantly reduced in IBD patient fecal samples (Omenetti & Pizarro, 2015). 
Considering how many treatments show efficacy, it is clear that there are many pathways 
leading to the complexity and downfall in identifying a complete cure. Instead, it appears 
that the long term treatment of IBD will require an approach that involves multiple 
mechanisms of action. 
 
Heme Oxygenase-1 as a Treatment Target 
 
Heme oxygenase-1(HO-1) has been identified recently as a new treatment target 
in IBD (Onyiah et al., 2013). HO-1 is an enzyme which degrades heme into the 
antioxidants biliverdin, iron, and carbon monoxide (CO) (Naito, Takagi, & Yoshikawa, 
2004). Biliverdin is possibly the most important product of this reaction, it leads to 
reactive oxygen species scavenging, anti-complement, and inhibition of neutrophil and 
CD8+ T-cell influx (Naito, Takagi, & Yoshikawa, 2004) (Figure 5). Oxidative stress 
plays a major role in the pathogenesis of colitis, and the byproducts generated by HO-1 
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makes it a natural source of induced antioxidants, which have been found to provide 
protection against IBD (Oz, Chen, McClain, & de Villiers, 2005). Additionally, oxidative 
stress has been found to result in dysfunctional DNA methyltransferases, which normally 
act as anti-inflammatory molecular switches by repressing TNFα production (Low, 2013, 
Marjoram et al., 2015).  In relation to recent work in T-regs and Th17 cell balance, in a 
recent DSS model based study, HO-1 induced by hemin was found to not only result in a 
depletion of Th17 cells but also an increase in the pool of T-regs compared to untreated 
controls (Zhang et al., 2014).  
 
Research Aims, Goals, and Hypothesis 
 
The primary research goal of this thesis was to assess the efficacy of heme 
oxygenase-1 (HO-1) on altering T-cell differentiation and ratios in an adoptive transfer 
model of CD4+ T-cell colitis in mice. Based on previous literature, it was hypothesized 
that hemin would have a profound effect in diminishing disease in an adoptive transfer 
model of colitis, measured by weight loss and video endoscopy score. Moreover, this 
effect would correlate with a reduction in pro-inflammatory cytokines and more 
specifically a skew away from a Th17 response. To assess this hypothesis, two specific 
aims work together to answer the primary objective. Details of the study design can be 
found in Table 1. 
 
Primary objective: Show disease reduction in an in vivo model of colitis and correlate 
this change with T-cell profile modulation and cytokine differences. 
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 Specific Aim 1: Show disease reduction by treatment with hemin using 
 compilation of measurements in a standard model of IBD. 
  Methods: Track weight change, evaluate disease via video    
  endoscopy, monitor blood/diarrhea presence around the rectum,   
  and colon weight/length change. 
    Expected results: There will be a reduction in disease   
    represented by reduction in weight loss, endoscopy score,   
    blood/diarrhea presence, and colon weight/length ratio. 
Specific Aim 2: Show a reduction in proinflammatory T-cells and  cytokines 
using FACS and immunoassays in a standard model of IBD. 
 Methods: Quantitate CD4+, CD4+CD25+, and CD4+CD39+ T-  
 cells using FACS analysis on the blood, spleen, and mesenteric   
 lymph nodes. Additionally, the blood, spleen, mesenteric lymph   
 nodes, and colon will be analyzed using immunoassays for IFN-γ,   
 IL-1b, IL-4, IL-6, IL-22, IL-10, IL-23, IL-12, IL-13, IL-17A, TNF- 
 α, and TGF-β1. 
  Expected Results: There will be a reduction in CD4+ and   
  CD4+CD39+ T-cells in the hemin treatment group as well   
  as an increase in CD4+CD25+ T-cells. Furthermore,   
  proinflammatory cytokines will be reduced in blood and   
  tissue samples. 
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Chapter II 
Materials and Methods 
 
Animals 
 
A total of 16 male C57BL/6-Rag2tm1Cgn/J and 10 male C57Bl/6 mice from 
Taconic Biosciences (Germantown, NY) were used in this study. RAG2 (recombination 
activating gene) is transcribed and translated into a protein primarily responsible for the 
rearrangement of genes encoding T and B cells receptors; without proper functional 
rearrangement the cells are signaled for apoptosis (Shinkai, 1992). The donor C57BL/6 
mice provide CD4+ T-cells that are able to be stimulated to differentiate and proliferate 
in the RAG2 knockout mice. The KO mice were bred on a C57BL/6 background and are 
MHC matched. These KO mice were used for the disease phase portion of the study, 
comprising two groups of 8 mice each.  
 
Adoptive Transfer Model of Colitis 
 
To obtain naive T-cells to induce colitis with, the spleens were harvested from the 
10 C57BL/6 donor mice and prepared for magnetic bead separation. First, the spleens 
were placed in ice cold PBS upon excision. Next, the spleens were homogenized using a 
gentleMACS dissociator (Miltenyi, San Diego, CA) in order to create a single cell 
suspension. Finally, the suspension of splenocytes was sorted using a MACS column 
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(Miltenyi, San Diego, CA) to isolate naïve T-cells, defined by the cell surface molecules 
CD4+CD62L+CD44-. Once sorted, the cells were counted and resuspended in PBS such 
that each recipient RAG2-/- mouse received a 200μl intraperitoneal dose containing 
0.5x10^6 naive CD4+ T-cells. When injected, the naive CD4+ T-cells are stimulated by 
interactions with the microbiome to proliferate and differentiate (Feng, Wang, Schoeb, 
Elson, & Cong, 2010).   
Outward signs of inflammation begin at 5-8 weeks after transfer, and can be 
detected by weight loss, video endoscopy, and the presence of blood and/or diarrhea near 
the rectum. After induction (Day 0), weight change and incidence of blood/diarrhea was 
recorded daily, and endoscopy performed once a week beginning day 14. On day 0 
animals began treatment with either PBS or hemin (50μg/kg) intraperitoneally twice a 
week until study conclusion. Additionally, at the time points indicated in Table 1, retro-
orbital blood collections were performed to count CD4+, CD25+, and CD39+ T-cells 
using fluorescence activated cell sorting(FACS) and IFN-γ, IL-1b, IL-4, IL-6, IL-22, IL-
10, IL-23, IL-12, IL-13, IL-17A, TNF-α, and TGF-β1 immunoassays. Also, mesenteric 
lymph nodes and spleen were collected at sacrifice and analyzed using the same methods 
as the blood. Finally, on day 28 and 56 animals were sacrificed for organ collection, 
specifically the colon, spleen, mesenteric lymph nodes, and blood. When the colon was 
excised it was measured, weighed, contents flushed, and trimmed to a length of 5 cm 
from the rectum where disease was assessed by endoscopy. From the 5 cm section a 1 cm 
middle piece was taken for multiplex ELISA cytokine immunoassays and HO-1 activity 
assay. The remaining two 2 cm sections were used for histopathological analysis, 
discussed further in the following sections.  
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FACS Analysis 
 
Whole blood samples were prepared in K2EDTA tubes each week beginning day 
14, except for day 49 due to equipment restrictions. Also, mesenteric lymph nodes and 
spleen were collected at sacrifice. Tissue and blood samples were prepared for analysis 
by FACS for the expression of cell surface markers CD4, CD8, CD25, and CD39, as 
follows: solid tissues were dissociated  in ice cold FACS buffer (5% BSA, 5mmol 
K3EDTA in 1x PBS) using the gentleMACS system to yield a single cell suspension. 
Blood and spleen were RBC lysed (BD Pharmlyse, Franklin Lakes, NJ) 1.0x10^6 cells 
were aliquoted and stained with fluorescent antibodies specific for CD4, CD8, CD25, and 
CD39, and run through a miltenyi MACSquant flow cytometer (Miltenyi, San Diego, 
CA). Data was analyzed using FlowJo software and representative FACS plots are seen 
in Figures 6 to 8. CD39+ T-cells were calculated as a percentage of CD4+ T-cells. The 
gating strategy, seen in Figure 9, was used to identify populations of CD4+ T-cells that 
are also CD39+ and CD25+. 
 
Multiplex Magnetic Bead Immunoassay 
 
A portion of the colon was used in multiplex cytokine panel immunoassays, to 
detect IFN-γ, IL-1b, IL-4, IL-6, IL-22, IL-10, IL-23, IL-12, IL-13, IL-17A, TNF-α, and 
TGF-β1 (EMD Millipore Corporation). Colon samples were prepared by low to medium 
homogenization for 30 seconds in PBS while on ice to prevent degradation. The protocol 
supplied by the vendor was as followed; briefly, the 96 well immunoassays were loaded 
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with appropriate standards and controls provided by the Milliplex MAP Kit, magnetic 
beads to mark the specific cytokines of interest, and homogenized sample. Following the 
2 hour incubation period, the plate was read using a Luminex200 to obtain the median 
fluorescent intensity (MFI) which was then used to calculate cytokine concentrations 
using the curve generated by the standards for each analyte. Day 28 tissues were not used 
in this analysis due to limited reagents.  
 
Video Endoscopy 
 
Beginning on Day 14 and then once weekly throughout the study duration, colitis 
severity was assessed in all animals using high definition video endoscopy where images 
were taken and colitis severity scored by a blinded observer according to the scoring 
scale seen in Figure 22 (Hamilton et al., 2011, Lyng, Stevens, Gordon, Watkins, & Sonis, 
2008). Animals were anesthetized using 2.5% isoflurane vapor, for each animal at each 
time point, the endoscope was placed into the rectum using a small amount of lubricant. 
A high definition camera was attached to the endoscope (Karl Storz, Germany) which 
was 14cm in length and rigid with a beveled tip. When the endoscope passed the rectum, 
a small amount of air was pushed into the colon through the endoscope biopsy channel to 
inflate, allowing visualization of the tissue. The endoscope was then carefully moved 
down the length of the colon pushing any stool, mucous, or blood towards the proximal 
end. While removing the endoscope the tissue was clear of debris and inflated to 
visualize and give the appropriate score by a blinded observer. Following the procedure 
all animals’ recovery from anesthesia was monitored. Video endoscopy can be a 
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powerful measure of colitis severity, in the adoptive transfer model used here the disease 
is mild-moderate compared to the more severe chemically induced models like DSS and 
TNBS. 
 
Histopathology 
 
Colon samples obtained from sacrificed animals were sectioned for 
histopathology. Of the 6-8cm colon tissue, two 2 cm sections were collected in 10% 
neutral buffered formalin. These sections were then stained with hematoxylin and eosin 
(H&E) and sectioned 8-10 times at 5-8µm thickness per 2cm tissue on each slide. 
Histology photos displaying disease progression for each group on days 28 and 56 are 
shown in Figures 10 and 11, selected by an unblinded observer guided by the colon 
histopathology scoring scale (Figure 12). 
 
Heme Oxygenase-1 Activity Assay 
 
A previously described enzyme activity assay for HO-1 was used, with 
modifications (Zhang et al., 2014). After running test samples using C57Bl/6 colon 
tissue, steps were taken to increase the sensitivity of the assay.  In order to compensate 
for the small protein content and sample size, changes were made to decrease the dilution 
of the sample. The original protocol is as follows “The colons were homogenized in 10 
mmol/liter HEPES, 32 mmol/liter sucrose, 1 mmol/liter dithiotreitol (DTT), 0.1 
mmol/liter EDTA, 10 μg/ml soybean trypsin inhibitor, 10 μg/ml leupeptin, and 2 μg/ml 
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aprotinin and centrifuged at 18,000 × g for 30 min at 4 °C. The supernatant was used to 
measure HO activity. The reaction mixture, consisting of 200 μl of sample homogenate, 
100 μl of normal liver cytosol (source of biliverdin reductase), 20 μmol/liter hemin, and 
0.8 mmol/liter NADPH, was incubated at 37 °C for 1 h. The optical density (OD) was 
measured between 464 and 530 nm (extinction coefficient, 40 mmol/liter/cm for 
bilirubin) to assess bilirubin production once the reaction was terminated by putting 
samples in an ice bath. Values were expressed as pmol of bilirubin formed per hour per 
milligram protein” (Zhang et al., 2014).  Here, the reaction mixture consisted of 100 μl of 
sample homogenate and 50 μl of normal liver cytosol. The OD was measured at 450 nm 
and 540 nm which were the closest filters available. 
 
Statistical Analysis 
 
All quantitative values are expressed as the average of the group ± standard error 
of the mean (SEM). All statistics except for endoscopy scores were analyzed and graphed 
using a one-tailed t-test between Vehicle and Treatment groups in Prism (Graphpad). 
Endoscopy scores were tested using Mann-Whitney U tests. P-values were considered 
significant if p≤0.05. Values falling below the limit of detection in the cytokine panels 
were expressed as 50% of the lowest standard. Values above the limit of detection in the 
cytokine panels were expressed as the highest standard detected. Animal number 4 had 
extremely high outliers found in the immunoassay data, as such the data was not included 
in the analysis. 
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Chapter III 
Results 
 
In-Life Phase 
 
Weight Change, Survival, and Diarrhea/Blood 
 
Weights were obtained daily throughout the course of the study and percent 
change was calculated each day relative to the baseline weight set on day 0. Over the 
duration of the study, no animals were sacrificed due to weight loss or morbidity 
however, one hemin treated animal was found dead on day 52. Disease in the adoptive 
transfer model takes roughly 25 to 40 days to initiate weight loss. Here, weight loss was 
observed in this window, beginning day 28. Weight change through day 28 and 56 
expressed as area under the curve (Figure 13) shows nearly identical weights on day 28 
and higher weights for the hemin group on day 56. Overall, the hemin group was trending 
with less weight loss than the vehicle group, however statistical significance was not 
reached until the final two days of the study (Days 55 and 56). Mean daily group weights 
(Figure 14) show similar weight change patterns, however the hemin group tended to 
have less weight loss especially towards the end of the study. Individual animal weight 
change (Figure 15) shows distribution within groups, the hemin group was mostly higher 
than the vehicle group other than one animal. Diarrhea and blood checks were performed 
daily, however there were no observed bouts of either. Colon weight and length was 
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measured when harvested and found no significant difference between the two groups 
(Figure 16). Additionally, although no toxic side effects were noticed, upon sacrifice the 
hemin treated animals had deposits of hemin in the abdomen (Figure 41). 
 
FACS Analysis 
 
Labels for CD4, CD8, CD25, and CD39 were used to determine T-cell levels. No 
distinct CD25+HIGH (T-regs) or CD8+ (Cytotoxic T-Cell) populations were identified 
indicating an accurate cell sort for naïve CD4+ T-cells. On day 56, the blood CD4+ T-
cell percentage was significantly higher in the vehicle group (Figure 17). Further, on days 
28, 35, 42, and 56 there were significantly increased levels of CD39+ cells, calculated as 
a percentage of CD4+ T-cells (Figure 18). In the mesenteric lymph nodes collected on 
days 28 and 56, CD4+ T-cells and CD4+CD39+ T-cells were the same for each group, 
however in the spleen while not significant there tended to be higher CD4+ and 
CD4+CD39+T-cell percentages in the vehicle group (Figures  19 and 20).  
 
Endoscopy Score 
 
Video endoscopic evaluation of the colon performed weekly beginning on day 14 
resulted in no significant differences between groups, however the average scores in the 
hemin group were trending lower beginning on day 35 (Figure 21). Representative 
images from each week (Figure 23 to 26), show gross morphological changes between 
groups. These images best represent the mean group values, selected by an unblinded 
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observer, and a trend can be seen with more disease severity in the vehicle group 
particularly at the last 3 evaluations where each animal reached a colitis score of 2, 
whereas the hemin group has animals with colitis scores of 1.  
 
Post-Life Phase 
 
Tissue Cytokine Levels 
 
Twelve cytokines were evaluated, IFN-γ, IL-1b, IL-4, IL-6, IL-22, IL-10, IL-23, 
IL-12, IL-13, IL-17A, TNF-α, and TGF-β1. Values were obtained for each in the blood 
plasma on day 28, 35, 49, and 56 and at sacrifice on day 56 the mesenteric lymph nodes, 
spleen, and colon. Figures displaying the complete results can be found in the appendix 
(Figures 27 to 40) 
On day 28 in the blood plasma, there were no significant differences between 
groups (Figure 27 and 28). However, the pro-inflammatory cytokines IFN-γ and TNF-α 
levels in the vehicle group were trending higher than the hemin group. This observation 
was confirmed by following findings on days 35 and 49 where the trend was still 
widening, and on day 56 where ultimately there was a significant difference (Figures 29 
to 34). Mean IL-17A values for each week of plasma samples were below the limit of 
detection (LOD), but on day 35 the findings showed a significant decrease in of IL-17A 
in the hemin treatment group (Figure 30). Again on days 49 and 56, IL-17A values were 
below the LOD but still trending with higher values for the vehicle group (Figures 32 and 
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34). Additionally, on days 49 and 56 TGF-β1 levels were trending with higher values in 
the hemin group (Figures 32 and 34). 
Mesenteric lymph nodes taken at study conclusion showed significant differences 
with higher values in the vehicle than the hemin for cytokines IL-12, IL-23, and IL-13 
(Figure 36). IL-1b, IL-4, IL-6, IL-10, and TNF-α tended to be higher in the vehicle group, 
while IL-22 and TGF-β1 were higher in the hemin group (Figures 35 and 36). The spleen 
samples had significant values for 10 of 12 cytokines tested, only IL-4 and TGF-β1 were 
not found to be significant. IL-4 appeared to be higher in the vehicle group but not 
significant (Figures 37 and 38). In the colon, TGF-β1 was significantly higher in the 
vehicle group (Figure 40). IFN-γ, IL-1b, IL-4, IL-6, IL-23, IL-12, IL-13, IL-17A, and 
TNF-α were trending higher in the vehicle group but not significant (Figures 38 and 39). 
 
Histopathology 
 
 Representative histopathology images show gross morphological changes in the 
epithelial and muscular layer of the colon (Figures 10 and 11). Disease progression 
marked by morphological changes can be seen including edema, neutrophil infiltrate, and 
crypt morphology loss. Figure 12 is a representative histopathology colon scoring scale 
with scoring descriptions. 
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Heme Oxygenase-1 Activity Assay 
 
No detectable changes in optical density were observed, therefor the presence of 
HO-1 was not confirmed. Limitations and future research based on this is discussed in the 
study limitations section. 
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Chapter IV 
Discussion 
 
Significance of Results 
 
Heme oxygenase-1 (HO-1) is an oxidative stress response enzyme that catalyzes 
the breakdown of heme into carbon monoxide, biliverdin, and iron (Figure 5) (Naito, 
Takagi, & Yoshikawa, 2004). HO-1 is a rate-limiting enzyme that has been identified as 
an autoimmune suppressor in a variety of disease models (Choi & Alam, 1996, Panahian, 
Yoshiura, & Maines, 2008). Recently, treatment with the HO-1 inducer hemin has been 
shown to have efficacy in the DSS-induced colitis model (Zhang et al., 2014). 
Specifically, numbers of pro-inflammatory Th17 cells were decreased and suppressor T-
regs were increased which resulted in a significant treatment effect, diminishing disease 
(Zhang et al., 2014). Here, we saw a similar effect on T-cell modulation in an adoptive 
transfer model of colitis using FACS analysis and immunoassays while monitoring 
disease severity using weight loss and video endoscopy as primary endpoints. 
Throughout the course of the 57 day study, animal body weights were obtained 
daily. Notably, both groups had similar weight change until separation began after day 
42, with the hemin treated animals tending to show less weight loss (Figure 14). Near 
study conclusion on days 55 and 56 the difference in weight change reached statistical 
significance, where the hemin group has shown an overall gain in weight. The individual 
weight change graph shows the distribution of weight loss within groups, where it can be 
seen that the hemin group animals are trending higher than vehicle with one exception 
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(animal #11) (Figure 15). Importantly, weekly endoscopic evaluation revealed that the 
vehicle group reached a peak score of 2 for all animals on day 42 which persisted until 
study conclusion, while the hemin group had an average score of 1.6, 1.6, and 1.8 on days 
42, 49, and 56 respectively. However, this effect did not reach statistical significance 
(Figure 21). Although endoscopy was not significant, a trend is seen in the representative 
photos, Figures 23 to 26, where the hemin treated animals have less tissue friability 
and/or bleeding. These findings together suggest a positive treatment trend for the hemin 
group. Colon weight to length ratios were calculated to determine gross physiological 
changes, but differences were not found between groups. 
To support these in-life endpoints, beginning on day 14, a small volume of 
peripheral blood (100µL) was collect from each animal once per week; plasma was 
collected for subsequent immunoassays, and the cellular portion was reserved for FACS 
analysis. In addition to blood, mesenteric lymph nodes, spleen, and colon were harvested 
and homogenized for these analyses at time of sacrifice (Table 1). First, CD4+ T-cell 
populations were identified by FACS analysis, which showed a significant increase of 
CD4+ numbers in the vehicle group compared to the hemin group on day 56 in the blood. 
We measured for CD25 and CD39 expression within the CD4+ populations, finding that 
there were no CD25 high events (Figure 6). T-regs are characterized by high expression 
levels of the cell surface marker CD25 (IL-2R) (Josefowicz, Lu, & Rudensky, 2012). 
With the results showing no CD25 high populations, and knowing that CD25+ cells were 
removed during the initial cell sort, we can conclude there are no significant true T-reg 
populations (Beyer, 2006). While this initially was seen as a deviation from the findings 
from the DSS models, we found that CD4+CD39+ T-cells were significantly increased in 
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the vehicle group each week beginning day 28 and persisted until study conclusion 
(Figure 18). The cell surface marker CD39 has been shown to be present on both 
pathogenic Th17 and T-regs (Bai et al., 2014, Dwyer et al., 2010). Since there are no T-
regs present as (defined here as CD4+CD25high), these data indicate a significant 
increase in the pool of Th17 cells in the vehicle group compared to the hemin. No 
significant differences were found in the spleen and mesenteric lymph nodes, using 
FACS analysis (Figures 19 and 20). 
Multiplex immunoassays were used to detect the presence of IFN-γ, IL-1b, IL-4, 
IL-6, IL-22, IL-10, IL-23, IL-12, IL-13, IL-17A, TNF-α, and TGF-β1 in the peripheral 
blood plasma, mesenteric lymph nodes, spleen, and colon. IFN-γ and TNF-α levels were 
both significantly elevated in the vehicle group compared to the hemin group on day 56 
in the blood. This finding suggests that hemin is suppressing the secretion and/or 
production of pro-inflammatory cytokines. Interestingly, IL-17A levels were found to be 
significantly increased on day 35 in the vehicle group, while trending similarly for the 
remainder of the study (the significance of this result is limited due to the mean IL-17A 
levels were below the limit of detection). Low levels of IL-17A suggest low overall 
levels of Th17 cells and/or a diminished response, however, the number of T-cells in the 
adoptive transfer model is much less than that of a wild type C57Bl/6 mouse; this would 
account for multiple target cytokines falling below the limit of detection (Figures 27 to 
40). In a wild type C57Bl/6 mouse lymphocytes comprise over 60% of the cells in the 
blood, compared to just over 10% on day 56 in the vehicle group (Figure 17) (JAX 
Physiological Data Summary - C57BL/6J, 2016). Supporting this is the finding that there 
were significantly increased levels of IL-17A in the spleen well over the limit of 
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detection (Figure 38) and the level of T-cells in the spleen were close to that of a wild 
type C57Bl/6 mouse spleen (Figure 19) (JAX Physiological Data Summary - C57BL/6J, 
2016). In the colon, TGF-β1, levels were significantly higher in the vehicle group than 
the hemin group (Figure 40). This finding is interesting because literature references 
indicate that TGF-β1 has a role in immunosuppression by modulating the activation, 
proliferation, and differentiation of T-cells (Letterio & Roberts, 1998). Further research 
has shown that TGF-β1 is needed for the function of Foxp3+ T-regs (Marie, Letterio, 
Gavin, & Rudensky, 2005). However, more recent research has shown that TGF-β1 is 
needed for the development of Th17 cells from naive T-precursors (Mangan et al., 2006, 
Qin et al., 2009). Here, our results corroborate the pro-Th17 activity of TGF-β1 findings, 
observing increased blood CD4+CD39+ T-cells and pro-inflammatory cytokines in the 
vehicle group in conjunction with higher TGF-β1 levels in the colon compared to the 
hemin treated group. In the mesenteric lymph nodes, IL-12 and IL-23 levels were 
significantly increased in the vehicle group again indicating an increase in Th17 load 
(Figure 36). Recent research that has found that IL-12 and IL-23 are primary cytokines in 
the development of Th17 cells (Teng et al., 2015). IL-13, also significantly increased in 
the vehicle group, is known to suppress inflammatory cytokine production, however, 
other research has shown that IL-13’s suppressive capabilities are lessened in diseased 
patients and in addition, IL-13 is involved in the induction of TGF-β1 secretion which we 
saw in this research (Fichtner-Feigl, Strober, Kawakami, Puri, & Kitani, 2005, 
KUCHARZIK et al., 1996, Wynn, 2003). Finally, the spleen saw significant cytokine 
changes in 10 of 12 cytokines evaluated (all except IL-17A and IL-4), with higher 
concentrations in the vehicle group which highlights the overall immunosuppressive 
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capabilities of hemin as a treatment leading to the effector subset (Th17) changes seen 
here (Figures 37 and 38). While IL-10 levels were significantly increased in the spleen, 
the fact that a suppressive cytokine is upregulated could simply indicate enhanced 
inflammation and disease which strengthens the case for hemin as an immunosuppressive 
treatment. Indeed, in the intestinal epithelium of CD patients IL-10 is significantly 
increased during inflammation in associated with IL-10 producing monocyte infiltrate 
(Marlow, 2013). 
The HO-1 activity assay did not detect any changes in activity between groups, 
the primary value needed to identify an increase in HO-1 as a product of bilirubin 
production. This could be due to lack of sensitivity of the assay, or the limited quantity of 
tissue available for use. Additionally, in the transgenic strain RAG2-/- mice there is likely 
to be different levels of expression of multiple factors in response to stress as a results of 
the absence of B or T-cells, other than the naive T-cells used to induce disease. 
 
Study Limitations 
 
While it is possible that treatment did not have a large effect on disease, the trends 
seen in the weight changes, AUC, endoscopy scores, and cytokine panels suggest an 
increase in group size would yield statistically significant differences. In addition to 
larger group sizes, additional groups could have been added, such as a naïve (no cell 
transfer) control and a Sn-protoporphyrin IX (SnPP) treatment group. SnPP, is a 
competitive inhibitor which also induces HO-1 but blocks enzyme activity (Zhang et al., 
2014).  Another limitation could be the hemin dose and/or frequency and duration of 
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dose. No toxic effects were observed, indicating that a larger or more frequent dose 
would be a possibility. Histopathology scoring, which requires a board certified 
pathologist and was outside of the budget could have been a more sensitive detection of 
disease than video endoscopy due to the low severity in the disease model compared to 
chemical models. 
The HO-1 activity assay did not result in any usable data, this could be due to the 
sensitivity of the assay. Researchers who have used this is the past did not indicate mass 
of tissue required for the assay; a relatively small 1 cm piece was used here to allow for 
the remained to be used for histopathology sectioning. Th17 cells were a main focus of 
these experiments, and IL-17A was used to infer an active Th17 response. However, the 
IL-17A ELISA yielded results below the limit of detection for many of the samples. It is 
possible that a more complete picture would be obtained by assessing the concentration 
of other IL-17 isoforms rather than solely focusing on IL-17A. Additionally, the lower T-
cell load and complete absence of B-cells in the adoptive transfer model compared to a 
naïve wild type mouse could be a major factor influencing the concentrations of 
cytokines; C57Bl/6 mice have on average 60% lymphocytes in their blood compared to 
just over 10% seen here (JAX Physiological Data Summary - C57BL/6J, 2016). Finally, 
there are commercially available assays used to quantify Th17, HO-1, and T-Reg 
ELISAs, however limited resources precluded their use in this case. and other methods of 
detection were chosen as substitutes (Th17/TGF-β1 multiplex, HO-1 activity assay, and 
FACS analysis).  
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Future Research Directions 
 
Research building on these results should include additional T-cell markers for 
FACS analysis, as the field has become increasingly aware that subsets of effector T-cells 
can be differentiated from one another using multiple disctinct cell markers. For example, 
CD161 combined with CD39 indicates a pathogenic Th17 cell, while Foxp3 with CD39 
indicates a T-regs (Bai et al., 2014, Dwyer et al., 2010). Moreover, analyzing 
transcription factors Foxp3 and ROR-γ by FACS would allow further characterization of 
T-cells. Using an ELISA to detect HO-1 would be a more accurate and reliable method 
for detection and would likely require less sample, allowing for more effective analysis 
using that tissue. In the adoptive transfer model of colitis, disease typically presents less 
severely than in chemical models as shown by the peak score of 2 via endoscopy (Figure 
21), as compared with an average peak score >2.5 in the DSS model 
("Colitis/Inflammatory Bowel Disease (IBD) | Biomodels", 2016). Due to this, 
histopathological scoring by a trained pathologist may be essential to identify subtle 
inflammatory damage by morphological changes 
An avenue to explore and expand upon these results would be to look at the role 
of integrins in Th17 development in this model using hemin as treatment. Research has 
shown that integrin αvβ8 activation of TGF-β1 is needed to induce Th17 differentiation 
(Pociask & Kolls, 2010). Here, we showed a significant increase in TGF-β1 in colon 
tissue; it would be important to determine if integrins are being affected as part of 
treatment and/or as part of the overall immunosuppressive capabilities of hemin. Finally, 
the data presented suggest the adoptive transfer model is a prime candidate for future 
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research focusing on TGF-β1 and T-cell development, which has reported conflicting 
results in the past. (Letterio & Roberts, 1998, Mangan et al., 2006, Marie, Letterio, 
Gavin, & Rudensky, 2005, Qin et al., 2009). 
 
Conclusion 
 
I hypothesized that hemin would upregulate HO-1 which then would have a 
powerful effect in diminishing disease determined by weight loss and video endoscopy 
outcomes and this effect would be associated with decreased pro-inflammatory cytokines 
and Th17 cell differentiation. Data from the adoptive transfer induced colitis model is 
presented showing significant decreases in CD4+ and CD4+CD39+ T-cells counts and 
pro-inflammatory cytokines IFN-γ and TNF-α together with positive trends in weight 
change, video endoscopy score, and other cytokines in the hemin treatment group. HO-1 
was unable to be detected and therefore cannot be positively identified as the treatment 
target. Additionally, since no T-reg population was identified it does not appear that 
hemin induces the proliferation of T-regs from naïve T-cells. Together, these data 
strongly suggest that hemin acts as an anti-inflammatory agent with T-cell modulatory 
effects.  
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Appendix 
 
 
Table 1. In-Life Study Design: 10 donor mice provided naïve CD4+ T-cells to induce 
colitis in 16 RAG2-/- mice. Collections, measurements, and dosing provided valuable 
data on disease progression. Sacrifice endpoints were used to detect changes in tissue 
samples colon, spleen, and mesenteric lymph nodes. 
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Figure 1. Insult to gut results in loss of bacterial balance and dysregulated immune 
response. Beneficial bacteria no longer provide protection against pathogens leading to an 
inflammatory cascade marked by Th17 proliferation (Gálvez, 2014). 
 
 
Figure 2. Naïve T-cells “Tn” have the potential to become many effector and T-regs. The 
cytokine milieu present drives production of specific subsets (Weaver, Harrington, 
Mangan, Gavrieli, & Murphy, 2006). 
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Figure 3.The complex relationship between T-reg and Th17 plays a significant role in the 
pathogenesis of IBD and highlights the importance in understanding the characteristics of 
each subset (Omenetti & Pizarro, 2015). 
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Figure 4. The magnetic cell sort for CD62L+CD44- and the previously described 
CD45+CD25- T-cell sort express naïve T-cell marker CD45RB+ as shown by FACS 
analysis. These cells are then resuspended and injected in mice to induce colitis 
("Colitis/Inflammatory Bowel Disease (IBD) | Biomodels", 2016). 
 
 
39 
 
 
Figure 5. Degradation of heme by HO-1 produces anti-inflammatory byproducts  
biliverdin, carbon monoxide, and Fe2+. These products lead to several anti-inflammatory 
effects such as ROS scavenging, neutrophil infiltrate inhibition, and anti-apoptosis 
(Naito, Takagi, & Yoshikawa, 2004). 
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Figure 6. Representative Blood FACS analysis measuring CD4+ T-cell counts and Plots 
which gated for CD39+ (Th17) on the Y-axis, and CD25+ (T-reg) on the X-axis. Blood 
was collected at timepoints detailed in table 1 and processed for FACS analysis. No 
CD25+ populations were found, but CD39+ populations are present but significantly 
smaller in the hemin treatment group at each timepoint. 
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Figure 7. Representative Mesenteric Lymph Node FACS analysis measuring CD4+ T-
cell counts and Plots which gated for CD39+ on the Y-axis, and CD25+ on the X-axis. 
Tissue was collected at timepoints detailed in table 1 and processed for FACS analysis. 
No CD25+ populations were seen but CD39+ populations are higher compared to blood, 
but no significant differences were found. 
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Figure 8. Representative Spleen FACS analysis measuring CD4+ T-cell counts and Plots 
which gated for CD39+ on the Y-axis, and CD25+ on the X-axis. Tissue was collected at 
timepoints detailed in table 1 and processed for FACS analysis. Similarly to the 
mesenteric lymph nodes, no CD25+ populations were seen but CD39+ populations are 
higher compared to blood, but no significant differences were found. 
 
 
 
 
 
Figure 9. FACS Gating strategy. Panel A is a side and forward scatter plot displaying 
overall cell size. Panel B is a side and forward scatter plot to isolate single cells and 
remove debris and any even ts that are not a single cell. Panel C is counting populations 
of CD4+ T-cells. Panel D is gated for CD39+ on the Y-axis and CD25+ on the X-axis. 
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Figure 10: Example Day 28 Histopathology analysis on colon sample shows sufficient 
disease induction. Panel A/C are a 100x magnification and Panel B/D are 200x. Black 
arrows indicate areas of increased edema and red arrows indicate areas of monocyte 
infiltrate indicating mild to moderate disease severity. 
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Figure 11: Example Day 56 Histopathology analysis on colon sample shows disease 
progress and severity. Panel A/C are a 100x magnification and Panel B/D are 200x. Black 
arrows indicate areas of increased edema, red arrows indicate areas of monocyte 
infiltrate, and blue arrows indicate areas where crypt morphology is perturbed indicating 
moderate to high disease severity. 
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Figure 12: “Histomorphology of colon tissue after transfer of CD4+CD45RBhi T cells into 
Rag1-ko mice representing scores according to scheme 3 (adoptive transfer colitis scale). 
A. Score 0: normal colon mucosa with intact epithelium; B. Score 1: scattered 
inflammatory cell infiltrates in the mucosa; C. Score 2: diffuse mucosal infiltrates 
without submucosal spreading and intact epithelial layer; D. Score 3: moderate 
infiltration of inflammatory cells into mucosa and submucosa with epithelial hyperplasia 
and goblet cell loss; E. Score 4: marked inflammatory cell infiltrates in mucosa and 
submucosa accompanied by crypt abscesses and loss of goblet cells and crypts; F. Score 
5: marked inflammatory cell infiltrates within the mucosa spreading to the submucosa 
going along with crypt loss and hemorrhage. Original magnification ×100; scale bars 100 
μm; arrows-inflammatory cell infiltrates within mucosa (solid) and submucosa (dotted); 
black arrowhead-crypt abscess, blue arrowhead-goblet cell loss; yellow arrowhead-crypt 
loss; red arrowhead-hemorrhage.” (Erben et al., 2014) 
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Figure 13. Weight changes represented by Area Under the Curve (AUC). Animal weights 
were measured daily throughout the study. Data is represented as group average ±SEM. 
n=3 at day 28, n=5 at day 56 for group 1 and n=4 on day 56 for group 2.  
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Figure 14. Mean Group Weight Change. Yellow = Vehicle, Blue= Hemin. Animal 
weights were measured daily throughout the study. Percent weight change was calculated 
relative to the starting weight on day 0. Data is represented as group average ±SEM. n=8 
per group.  
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Figure 15. Individual Weight Change. Yellow = Vehicle, Blue= Hemin. Animal weights 
were measured daily throughout the study. Percent weight change was calculated relative 
to the starting weight on day 0.  
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Figure 16. Mean Group Colon Length/Weight (g/cm). Colon was excised at sacrifice on 
day 28 and 56, flushed with saline and measured for weight and length. Data is 
represented as group average ±SEM. n=3 at day 28, n=5 at day 56 for group 1 and n=4 on 
day 56 for group 2.  
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Figure 17. Mean blood CD4+ T-cell percentages. Blood was collected at timepoints in 
table 1 and processed for FACS analysis of CD4 expression. Data is represented as group 
average ±SEM. n=8 per group on days 14 and 28, n=5 per group on days 35 and 42, and 
n=5 at day 56 for group 1 and n=4 on day 56 for group 2. *: p<0.05 as assessed by one 
tailed Student’s T test.
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Figure 18. Mean blood CD4+CD39+ T-cell percentages. Blood was collected at 
timepoints in table 1 and processed for FACS analysis of CD4 and CD39 expression. 
Data is represented as group average ±SEM. n=8 per group on days 14 and 28, n=5 per 
group on days 35 and 42, and n=5 at day 56 for group 1 and n=4 on day 56 for group 2. 
*: p<0.05 as assessed by one tailed Student’s T test. 
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Figure 19. Mean tissue CD4+ T-cell. Tissue was collected at timepoints in table 1 and 
processed for FACS analysis of CD4 expression. Data is represented as group average 
±SEM. n=3 on day 28, and n=5 at day 56 for group 1 and n=4 on day 56 for group 2.  
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Figure 20. Mean tissue CD4+ CD39+ T-cell. Tissue was collected at timepoints in table 1 
and processed for FACS analysis of CD4 and CD39 expression. Data is represented as 
group average ±SEM. n=3 on day 28, and n=5 at day 56 for group 1 and n=4 on day 56 
for group 2. 
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Figure 21. Mean video endoscopy scores. Colitis was assessed by video endoscopy at the 
timepoints indicated in table 1 and scored using the colitis scoring scale shown in Figure 
10. Data is represented as group average ±SEM. n=8 per group on days 14, 21, and 28, 
n=5 per group on days 35, 42, and 49 and n=5 at day 56 for group 1 and n=4 on day 56 
for group 2. 
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Figure 22. Video Endoscopy Scoring Scale developed by Biomodels, LLC with 
descriptions for each score. Escalating from a score of 0-4 disease progression is 
identified by changes in vascularity, edema, bleeding, erosion, and ulceration (Hamilton 
et al., 2011, Lyng, Stevens, Gordon, Watkins, & Sonis, 2008) 
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Figure 23. Day 14 and Day 21 representative endoscopy images. Video endoscopy 
performed at timepoints indicated in table 1 and pictures were taken of the most diseased 
area. Group averages are shown for comparison purposes. n=8 per group 
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Figure 24. Day 28 and Day 35 representative endoscopy images. Video endoscopy 
performed at timepoints indicated in table 1 and pictures were taken of the most diseased 
area. Group averages are shown for comparison purposes. n=8 per group on day 28 and 
n=5 on day 35. 
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Figure 25. Day 42 and Day 49 representative endoscopy. Video endoscopy performed at 
timepoints indicated in table 1 and pictures were taken of the most diseased area. Group 
averages are shown for comparison purposes. n=5 per group 
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Figure 26. Day 56 representative endoscopy images. Video endoscopy performed at 
timepoints indicated in table 1 and pictures were taken of the most diseased area. Group 
averages are shown for comparison purposes. n=5 for group 1 and n=4 for group 2. 
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Figure 27. Day 28 Plasma Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection.  
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Figure 28. Day 28 Plasma Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. 
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Figure 29. Day 35 Plasma Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection.  
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Figure 30. Day 35 Plasma Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 31. Day 49 Plasma Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. 
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Figure 32. Day 49 Plasma Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. 
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Figure 33. Day 56 Plasma Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 34. Day 56 Plasma Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 35. Day 56 Mesenteric Lymph Node Multiplex Graph Part 1. Plasma was 
collected at the timepoints indicated in Table 1. Samples were analyzed using multiplex 
ELISA. Data is represented as group average ±SEM. n=8 per group. LOD: Limit of 
detection.  
69 
 
 
Figure 36. Day 56 Mesenteric Lymph Node Multiplex Graph Part 2. Plasma was 
collected at the timepoints indicated in Table 1. Samples were analyzed using multiplex 
ELISA. Data is represented as group average ±SEM. n=8 per group. LOD: Limit of 
detection. *: p<0.05 as assessed by one tailed Student’s T test. 
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Figure 37. Day 56 Spleen Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 38. Day 56 Spleen Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 39. Day 56 Colon Multiplex Graph Part 1. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection.  
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Figure 40. Day 56 Colon Multiplex Graph Part 2. Plasma was collected at the timepoints 
indicated in Table 1. Samples were analyzed using multiplex ELISA. Data is represented 
as group average ±SEM. n=8 per group. LOD: Limit of detection. *: p<0.05 as assessed 
by one tailed Student’s T test. 
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Figure 41. Representative Necropsy Photos. Group 1 (top) is normal and Group 2 
(bottom) hemin deposits (red arrows) are seen in peritoneal cavity.  
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